International Stem Cell Corporation Receives Key Stem Cell Patent in AustraliaMarketwired (press release)CARLSBAD, CA–(Marketwired – Oct 31, 2017) – International Stem Cell Corporation ( OTCQB : ISCO) (www.internationalstemcell.com), a California-base… Continue reading
Business Wire (press release) |
RenovaCare SkinGun™ Stem Cell Sprayer on Exhibit at the Science Museum in London
Business Wire (press release) NEW YORK & PITTSBURGH & BERLIN–(BUSINESS WIRE)–RenovaCare, Inc. (OTCQB: RCAR), developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today … |
|
NSCLC: Immunotherapy Beyond Progression
OncLive Benjamin Besse, MD, PhD: I think treatment beyond progression is not an issue of immunotherapy, it’s a general concern. It may be a good strategy with some TKIs, sometimes with chemotherapy, and with immunotherapy. It’s always the same. There is not 1 … |
|
Sanofi drops Voyager’s phase 2/3 Parkinson’s gene therapy
FierceBiotech Sanofi has walked away from the Parkinson’s gene therapy covered by its $845 million alliance with Voyager Therapeutics. The decision gives Voyager the full global rights to VY-AADC but leaves it without a partner as it gears up for a pivotal global … |
|
Sanofi drops Voyager’s phase 2/3 Parkinson’s gene therapy
FierceBiotech Sanofi has walked away from the Parkinson’s gene therapy covered by its $845 million alliance with Voyager Therapeutics. The decision gives Voyager the full global rights to VY-AADC but leaves it without a partner as it gears up for a pivotal global … |
|
Sanofi drops Voyager’s phase 2/3 Parkinson’s gene therapy
FierceBiotech Sanofi has walked away from the Parkinson’s gene therapy covered by its $845 million alliance with Voyager Therapeutics. The decision gives Voyager the full global rights to VY-AADC but leaves it without a partner as it gears up for a pivotal global … |
|
Sanofi drops Voyager’s phase 2/3 Parkinson’s gene therapy
FierceBiotech Sanofi has walked away from the Parkinson’s gene therapy covered by its $845 million alliance with Voyager Therapeutics. The decision gives Voyager the full global rights to VY-AADC but leaves it without a partner as it gears up for a pivotal global … |